中信证券研报称未来3年医美行业有望保持高个位数的稳健增长行业结构性机会突出：1）部分医美材料仍存在赛道红利如再生微球领域以及尚未有首证落地的PDRN、ECM、丝素蛋白、PHA等材料；2）上游具备平台化赋能能力的产品型公司；3）下游具备高美誉度、整合上游资源、以综合解决方案保持差异性等能力的医美终端机构。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.